Biotransformation of Cobicistat: Metabolic Pathways and Enzymes

Author(s): Pengcheng Wang , Amina I. Shehu , Ke Liu , Jie Lu , Xiaochao Ma .

Journal Name: Drug Metabolism Letters

Volume 10 , Issue 2 , 2016

Become EABM
Become Reviewer

Graphical Abstract:


Background: Cobicistat (COBI) is a pharmacoenhancer for antiretroviral therapy.

Objective: The current study was designed to profile the metabolic pathways of COBI and to determine the enzymes that contribute to COBI metabolism.

Method: We screened COBI metabolites in mice and human liver microsomes. We also used cDNAexpressed human cytochromes P450 (CYPs) to explore the role of human enzymes in COBI metabolism.

Results: Twenty new and three known metabolites of COBI were identified in mouse urine and feces. These new metabolic pathways of COBI include glycine conjugation, N-acetyl cysteine conjugation, morpholine ring-opening, and thiazole ring-opening. Twelve of COBI metabolites were further confirmed in mouse and human liver microsomes, including nine new metabolites. Consistent with the previous report, CYP3A4 and CYP2D6 were determined as the major enzymes that contribute to COBI metabolism.

Conclusion: This study provided a full map of COBI metabolism. These results can be used to manage CYP-mediated drug-drug interactions and adverse drug reactions that are associated with COBI-containing regimens in human.

Keywords: Cobicistat, CYP2D6, CYP3A4, cytochrome P450, drug metabolism.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [111 - 123]
Pages: 13
DOI: 10.2174/1872312810666160303112212
Price: $58

Article Metrics

PDF: 31